Vol. 14 No. 1 (2022): Archives of Public Health
Clinical Science

Evaluation of (1,3)--d-glucan assay in diagnosis of invasive fungal infections with Aspergillus

Gordana Mirchevska
Institute of Microbiology and Parasitology, “50 Divizija”6, Faculty of Medicine,“Ss.Cyril and Methodius University” in Skopje, Republic of North Macedonia
Zaklina Cekovska
Institute of Microbiology and Parasitology, “50 Divizija”6, Faculty of Medicine,“Ss.Cyril and Methodius University” in Skopje, Republic of North Macedonia
Ana Kaftandzieva
Institute of Microbiology and Parasitology, “50 Divizija”6, Faculty of Medicine,“Ss.Cyril and Methodius University” in Skopje, Republic of North Macedonia
Zorica Zafirovik
University Clinic for Dermatology, “Mother Theresa” Campus, Ss.Cyril and Methodius University” in Skopje, Republic of North Macedonia
Elena Trajkovska-Dokic
Institute of Microbiology and Parasitology, “50 Divizija”6, Faculty of Medicine,“Ss.Cyril and Methodius University” in Skopje, Republic of North Macedonia

Published 2022-06-23

Keywords

  • Aspergillus,
  • invasive fungal infection,
  • 1,3-ß-D-glucan panfungal marker,
  • BAL culture,
  • diagnosis

How to Cite

1.
Mirchevska G, Cekovska Z, Kaftandzieva A, Zafirovik Z, Trajkovska-Dokic E. Evaluation of (1,3)--d-glucan assay in diagnosis of invasive fungal infections with Aspergillus . Arch Pub Health [Internet]. 2022 Jun. 23 [cited 2022 Aug. 14];14(1). Available from: https://www.id-press.eu/aph/article/view/6045

Abstract

Invasive fungal infections caused by Aspergillus are a significant problem in immunocompromised and critically ill patients and associated with increased morbidity and mortality. Early diagnosis of invasive aspergillosis is still a big clinical and diagnostic challenge. Conventional methods are not sensitive enough, and therefore, there is a need for rapid, more sensitive methods for early diagnosis of invasive fungal infections with Aspergillus. The aim of this study was to evaluate the diagnostic performance, sensitivity and specificity of serological panfungal (1,3)-b-D-glucan marker compared to conventional method for diagnosis of invasive fungal infections with Aspergillus. Material and methods: Specimens of 125 patients divided into 4 groups (group I - immune deficiency, group II - prolonged ICU stay, group III - chronic aspergillosis, group IV - cystic fibrosis), classified according to clinical diagnosis and EORTC/MSG criteria, were analyzed at the Institute of Microbiology and Parasitology, with conventional and serological methods, during a period of two years. Results: A total of 71 isolates of Aspergillus were confirmed in this study. Four isolates were recovered from bloodculture of patients with primary immune deficiency. With BAL culture, Aspergillus was detected in the group of chronic aspergillosis (63.33%), followed by the groups of cystic fibrosis (56.67%), primary immune deficiency (51.43%), and the group with prolonged ICU stay (43.33%). Sensitivity and specificity of BAL culture were: 64.29% and 100%, 59.09% and 100%, 54.55% and 12.5%, 100% and 54.17%, in I, II, III and IV group, respectively. In 79.1% (53/67) from positive BAL cultures in all groups, A. fumigatus was confirmed, of which, 32.1% (17/53) in group III, followed by group I – 26.42% (14/53) and group IV – 26.42% (14/53), and 15.1% (8/53) in group II. Other species confirmed in BAL were A. flavus 16.42% (11/67) and A.terreus 4.48% (3/67). Sensitivity and specificity of the serological panfungal (1,3)-b-D-glucan (BDG) marker were: 64.71% and 85.71%, 50% and 87.5%, 36.36% and 50%, in groups I, II and III, respectively. No positive findings of the panfungal (1,3)-b-D-glucan (BDG) marker were found in the group with cystic fibrosis. Conclusion: The results obtained in this study have demonstrated that a positive (1,3)-b-D-glucan assay highlights the value of this test as a diagnostic adjunct in the serodiagnosis of invasive fungal infections with Aspergillus, and along with the results from conventional mycological investigation, helped in reaching a timely antifungal treatment with a favorable clinical outcome.

 

Downloads

Download data is not yet available.

References

  1. Pagano L, Mayor S. Invasive fungal infections in high-risk patients: report from TIMM-8 2017. Future Sci OA. 2018;4(6):FSO307.
  2. Latgé JP, Chamilos G. Aspergillus fumigatus and Aspergillosis in 2019. Clin Microbiol Rev. 2019;33(1):e00140-18.
  3. Tsitsikas DA, Morin A, Araf S, et al. Impact of the revised (2008) EORTC/MSG definitions for invasive fungal disease on the rates of diagnosis of invasive aspergillosis. Med Mycol. 2012;50(5):538-542.
  4. Raveendran S, Lu Z. CT findings and differential diagnosis in adults with invasive pulmonary aspergillosis. Radiology of Infectious Diseases. 2018; 5(1):14-25.
  5. Barton RC. Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome. Scientifica (Cairo). 2013;2013:459405.
  6. Theel ES, Doern CD. β-D-glucan testing is important for diagnosis of invasive fungal infections. J Clin Microbiol. 2013;51(11):3478-3483.
  7. Sulahian A, Porcher R, Bergeron A, et al. Use and limits of (1-3)-β-d-glucan assay (Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of invasive aspergillosis. J Clin Microbiol. 2014;52(7):2328-2333.
  8. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, et al. β-D-Glucan Assay for the diagnosis of invasive fungal infections: A Meta-analysis. Clinical Infectious Diseases. 2011;52(6):750–770.
  9. Kontoyiannis DP, Sumoza D, Tarrand J, Bodey GP, Storey R, Raad II. Significance of aspergillemia in patients with cancer: a 10-year study. Clin Infect Dis. 2000;31(1):188-189.
  10. Girmenia C, Nucci M, Martino P. Clinical significance of Aspergillus fungaemia in patients with haematological malignancies and invasive aspergillosis. Br J Haematol 2001;114(1):93-98.
  11. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore). 2000;79(4):250-260.
  12. Simoneau E, Kelly M, Labbe AC, Roy J, Laverdière M. What is the clinical significance of positive blood cultures with Aspergillus sp in hematopoietic stem cell transplant recipients? A 23 year experience. Bone Marrow Transplant 2005;35(3):303-306.
  13. Vetter E, Torgerson C, Feuker A, et al. Comparison of the BACTEC MYCO/F Lytic bottle to the isolator tube, BACTEC Plus Aerobic F/bottle, and BACTEC Anaerobic Lytic/10 bottle and comparison of the BACTEC Plus Aerobic F/bottle to the Isolator tube for recovery of bacteria, mycobacteria, and fungi from blood. J Clin Microbiol 2001;39(12):4380-4386.
  14. Lopes Bezerra LM, Filler SG. Interactions of Aspergillus fumigatus with endothelial cells: internalization, injury, and stimulation of tissue factor activity. Blood 2004;103(6):2143-2149.
  15. Thuret G, Carricajo A, Vautrin AC, et al. Efficiency of blood culture bottles for the fungal sterility testing of corneal organ culture media. Br J Ophthalmol 2005;89(5):586-590.
  16. Loeffler J, Kloepfer K, Hebart H, et al. Polymerase chain reaction detection of Aspergillus DNA in experimental models of invasive aspergillosis. J Infect Dis 2002;185:1203–1206.
  17. Tashiro T, Izumikawa K, Tashiro M, et al. Diagnostic significance of Aspergillus species isolated from respiratory samples in an adult pneumology ward. Med Mycol 2011;49(6):581-587.
  18. Meyohas MC, Roux P, Poirot JL, Meynard JL, Frottier J. Aspergillosis in acquired immunodeficiency syndrome. Pathol Biol (Paris). 1994;42(7):647-51.
  19. Lortholary O, Meyohas MC, Dupont B, et al. Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases. French Cooperative Study Group on Aspergillosis in AIDS. Am J Med. 1993;95(2):177-187.
  20. Mennink-Kersten MA, Ruegebrink D, Wasei N, Melchers WJ, Verweij PE. In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. J Clin Microbiol 2006;44(5):1711-1718.
  21. Zarrinfar H, Mirhendi H, Makimura K, Satoh K, Khodadadi H, Paknejad O. Use of mycological, nested PCR, and real-time PCR methods on BAL fluids for detection of A. fumigatus and A. flavus in solid organ transplant recipients. Mycopathologia. 2013;176(5-6):377-85.
  22. Ader F. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: an emerging fungal disease. Curr Infect Dis Rep 2010;12(6):409-16.
  23. Vandewoude KH, Blot SI, Depuydt P, et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care 2006;10(1):R31.
  24. Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, et al. Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care. 2005;9(3):R191-9.
  25. Khasawneh F, Mohamad T, Moughrabieh MK, Lai Z, Ager J, Soubani AO. Isolation of Aspergillus in critically ill patients: a potential marker of poor outcome. J Crit Care. 2006;21(4):322-327.
  26. Perfect JR, Cox GM, Lee JY, et al; Mycoses Study Group. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis. 2001;33(11):1824-33.
  27. Sisodia J, Bajaj T. Allergic Bronchopulmonary Aspergillosis. [Updated 2021 Aug 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542329/
  28. Lahmer T, Rasch S, Schnappauf C, et al. Comparison of serum galactomannan and 1,3-Beta-D-Glucan determination for early detection of invasive pulmonary aspergillosis in critically ill Patients with hematological malignancies and septic shock. Mycopathologia. 2016;181(7-8):505-511.
  29. Cai X, Ni W, Wei C, Cui J. Diagnostic value of the serum galactomannan and (1, 3)-β-D-glucan assays for invasive pulmonary aspergillosis in non-neutropenic patients. Intern Med 2014;53(21):2433-2437.
  30. Lahmer T, Neuenhahn M, Held J, Rasch S, Schmid RM, Huber W. Comparison of 1,3-β-d-glucan with galactomannan in serum and bronchoalveolar fluid for the detection of Aspergillus species in immunosuppressed mechanical ventilated critically ill patients. J Crit Care. 2016;36:259-264.
  31. Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder A, Williams D. Serum glucan levels are not specific for presence of fungal infections in intensive care units. Clin Diagn Lab Immunol. 2003;10:882-5.
  32. Kami M, Tanaka Y, Kanda Y, et al. Computed tomographic scan of the chest, latex agglutination test and plasma (1AE3)-beta-D-glucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients. Haematologica. 2000;85(7):745-752.
  33. Theel ES, Jespersen DJ, Iqbal S, et al. Detection of (1, 3)-β-D-glucan in bronchoalveolar lavage and serum samples collected from immunocompromised hosts. Mycopathologia. 2013;175(1-2):33-41.
  34. Mutschlechner W, Risslegger B, Willinger B, et al. Bronchoalveolar Lavage Fluid (1,3)β-D-Glucan for the Diagnosis of Invasive Fungal Infections in Solid Organ Transplantation: A Prospective Multicenter Study. Transplantation. 2015;99(9):e140-e144.
  35. Ahmad S, Khan ZU, Theyyathel AM. Diagnostic value of DNA, (1-3)-beta-d-glucan, and galactomannan detection in serum and bronchoalveolar lavage of mice experimentally infected with Aspergillus terreus. Diagn Microbiol Infect Dis. 2007;59(2):165-171.